[Danger of hyperuricemia in the treatment of acute leukemia, lymphosarcoma and reticulosarcoma].
D000208:Acute Disease; D000493:Allopurinol / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D015122:Mercaptopurine / Q000009:adverse effects; D008727:Methotrexate / Q000009:adverse effects; D011241:Prednisone / Q000009:adverse effects; D014527:Uric Acid / Q000097:blood*; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D014527:Uric Acid; D000493:Allopurinol; D015122:Mercaptopurine; D014969:Xanthine Oxidase; D011241:Prednisone; D008727:Methotrexate
O niebezpieczeństwie hiperuricemii w leczeniu ostrej białaczki, miesaka limfatycznego i siateczki